Clenbuterol to Target DUX4 in FSHD
NCT06721299
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Kansas City, Kansas, United States
View Trial DetailsNCT Number: NCT06847282
The primary goal of this study is to validate motor and functional outcomes and refine clinical trial strategies for pediatric-onset FSHD
Interested in participating?
Request Info5 year–17 year
All sexes
Observational
Murdoch Children's Research Institute, Melbourne, Australia
MOVE Peds is a prospective 2-year study recruiting eighty pediatric participants to accelerate therapeutic development for pediatric-onset FSHD. The study aims to validate outcomes and refine clinical trial strategies. Previous cross-sectional studies suggest that younger age of onset is linked to greater clinical severity and that having 1-3 D4Z4 repeats is associated with extra-muscular complications in pediatric FSHD.
Prospective studies in early-onset FSHD have been limited by the small number of sites and low recruitment and follow-up rates. Early-onset pediatric FSHD is of high interest to drug companies because:
The FSHD CTRN's previous research showed that the FSHD composite functional measure (FSHD-COM), reachable workspace (RWS), and quantitative MRI measures (qMRI) are responsive to disease progression or treatment in adults with FSHD and correlate with performance. Investigators hypothesize that early changes in qMRI in pediatric subjects will predict 2-year changes in FSHD-COM Peds or RWS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline-2 years
Investigators will collect the FSH-Composite outcome measure for children and adolescents. This measure assesses multiple body regions identified as important by patients, including leg function, shoulder and arm function, trunk function, hand function, and functional balance. The FSHD-COM Peds has been modified to include lighter weights for shoulder abduction and flexion, as well as elbow flexion, to accommodate the motor development and lower strength levels seen in children. Although the FSHD-COM Peds involves different measurements for each body region, these measurements are combined to produce a single composite score. The total score for the FSHD-COM Peds is out of 84, representing one comprehensive outcome measure
Time frame: Baseline-2 years
Subjects are seated in front of a stereo-camera and perform a standardized upper extremity movement protocol under the supervision of a study clinical evaluator. Five-hundred-gram wrist weights will be added. The standardized simple set of movements consist of lifting the arm from the resting position to above the head while keeping the elbow extended, performing the same movement in vertical planes at around 0, 45, 90, 135 degrees. The second set of movements consists of horizontal sweeps at the level of the umbilicus and shoulder.
Time frame: Baseline-2 years
quantitative MRI measurements are considered gold standard for lean muscle volume measurement and disease biomarkers (fat volumes, fat faction, and STIR+ presence) that may be modulated by treatment. Muscle fat replacement and free-water hyperintensity indicate early disease changes before functional performance is affected. Muscles with an intermediate fat fraction (10-55%) predict disease progression over 1-2 years.
Investigators will use a whole-body MRI and will find the fat fraction % in pediatric subjects and compare these measurements with other factors to create a composite score over a two-year period
Time frame: Baseline-2 years
Quantitative MRI measurements are considered the gold standard for assessing lean muscle volume and disease biomarkers (fat volumes vs. lean muscle volumes and STIR+ presence) that may be modulated by treatment. Muscle fat replacement and free-water hyperintensity indicate early disease changes before functional performance is affected. Muscles with low lean muscle volume and an intermediate fat fraction (10-55%) predict disease progression over 1-2 years.
Investigators will use whole-body MRI to measure lean muscle volume (mL) in pediatric subjects and compare these measurements with other factors to create a composite score over a two-year period.
Time frame: Baseline-2 years
Quantitative MRI measurements are considered the gold standard for assessing lean muscle volume and disease biomarkers (fat volumes, fat fraction and STIR+ presence) that may be modulated by treatment. The use of MRI has shown as a technique to predict disease progression.
Investigators will use whole-body MRI to measure total volume (mL) in pediatric subjects and compare these measurements with other factors to create a composite score over a two-year period. This refers to the overall volume of a specific tissue or organ measured in milliliters (mL) using MRI.
Time frame: Baseline-2 years
Quantitative MRI measurements are considered the gold standard for assessing lean muscle volume and disease biomarkers, such as the percentage of lean muscle volume with Short Tau Inversion Recovery (STIR) enhancement. STIR MRI helps predict disease progression by highlighting areas of inflammation and edema within muscle tissue. This provides valuable insights into underlying disease processes, aiding in the prediction of progression and guiding treatment decisions.
Investigators will use whole-body MRI to measure STIR positivity, indicating inflammation and edema, in pediatric subjects. These measurements will be compared with other factors to create a composite score over a two-year period.
Time frame: Baseline-2 years
an instrument developed by the NIH PROMIS initiative. It generates scores for physical function and the impact of physical limitations on daily life. Participants will answer questions about how often they engage in physical activity, ranging from 0 days to 6-7 days per week. Higher scores indicate greater levels of physical activity.
Time frame: Baseline-2 years
assess the impact of fatigue on individuals with neurological conditions, measuring their severity, frequency, and effects on daily activities and quality of life using a 5- point rating system (1 being never and 5 being always).
Time frame: Baseline-2 years
is a 5-item questionnaire which assesses the physical impact of facial weakness. The responses (graded 1-5, 5 being no difficulty and 1 being unable to do) are summed to create a total score, which is then converted into a percentage scale. A score of 100% represents normal function, while lower scores indicate increasing levels of disability.
Time frame: Baseline-2 years
measures how well people with neuromuscular disorders can perform daily activities. It includes 22 questions about tasks such as dressing, bathing, and walking, with difficulty rated as impossible, difficult, or easy.
Time frame: Baseline-2 years
is a tool used to screen for emotional and behavioral problems in children and adolescents aged 2 to 17. It consists of 25 questions divided into five categories: emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior. Each item is rated on a 3-point scale (0= not true, 1 = somewhat true and 2 = certainly true)
Time frame: Baseline-2 years
Is a rating scale that patients can use to measure how severe they feel their symptoms are. Patients rate their condition on a scale from 1 (Normal) to 4 (Severe). This will serve as one of the study anchors.
Time frame: Baseline-2 years
is an instrument developed to assess quality of life and how disease has changed since last visit. the purpose of the "domain-delta" questionnaire is to determine each patient's perceived change in their health-related quality-of-life in the last 6-months. This questionnaire will inquire about total health as well as health related to 14 subdomains self-identified as important by patients during development of the FSHD Health Index. Participants indicate their perceived change by answering if an area "is a lot worse", "is a little worse", "there has been no change", "it is a little better", or "it is a lot better" for each subdomain. This will serve as one of the other anchors in the study.
Time frame: Baseline-2 years
a tool used by clinicians to evaluate motor abilities in individuals with dysferlinopathy, a type of muscular dystrophy. It measures how well patients can perform various physical tasks, helping to track the progression of the disease. This assessment is useful for both walking and non-walking patients, providing important information to guide treatment and care plans. This will be used in comparison to how well the FSHD-COM Peds assessing subjects
Time frame: Baseline-2 years
an assessment tool used to evaluate upper limb function in individuals with muscular dystrophies, such as Duchenne muscular dystrophy. It measures the ability to perform various motor tasks, providing insights into the strength and mobility of the arms and hands. The PUL helps track disease progression and guides treatment decisions by capturing detailed information about upper limb capabilities. This will be helpful in assessing Cohort two as well as will be utilized to the FSHD-COM Peds and RWS.
Time frame: Baseline-2 years
is a fixed-distance assessment used to measure an individual's maximum ambulatory ability. Participants are asked to walk or run 100 meters as quickly as they can, depending on their capability. This test is commonly used in research to evaluate physical performance and mobility, particularly in individuals with conditions affecting their walking ability. It helps researchers track changes in mobility over time and assess the effectiveness of interventions aimed at improving walking speed and endurance
Time frame: Baseline-2 years
assess the impact of pain on individuals with neurological conditions, measuring their severity, frequency, and effects on daily activities and quality of life using a 5- point rating system (1 being never and 5 being always).
Time frame: Baseline-2 years
Is a rating scale that patients can use to measure if any change in severity has occurred since being in the study. patient rate their change on a scale from 1 to 7 (1 being no change or worse and 7 being a great deal better or improvement that has made all the difference). This will serve as one of the study anchors.
Contact information is provided by the study sponsor or research team.
Michaela Walker, MPH
CONTACT
Rebecca Clay, BS
CONTACT
University of Kansas Medical Center
Other
Acronym: MOVE Peds
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06721299
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Kansas City, Kansas, United States
View Trial DetailsNCT07409142
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, FSH
Randolph, Massachusetts, United States
View Trial DetailsNCT06227182
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT06517498
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Xi'an, Shaanxi, China
View Trial Details